Article PDF
Avoid common mistakes on your manuscript.
References
Birks EJ, Tansley PD, Hardy J et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 2006;355:1873–84.
Cooley DA. The total artificial heart. Nat Med 2003;9:108–11.
DeBakey ME. A miniature implantable axial flow ventricular assist device. Ann Thorac Surg 1999;68:637–40.
Deng MC, Edwards LB, Hertz MI et al. Mechanical circulatory support device database of the International Society for Heart and Lung Transplantation: second annual report–2004. J Heart Lung Transplant 2004;23:1027–34.
Deng MC, Edwards LB, Hertz MI et al. Mechanical circulatory support device database of the International Society for Heart and Lung Transplantation: third annual report–2005. J Heart Lung Transplant 2005;24:1182–7.
Frazier OH, Gemmato C, Myers TJ et al. Initial clinical experience with the HeartMate II axial-flow left ventricular assist device. Tex Heart Inst J 2007;34:275–81.
Frazier OH, Rose EA, McCarthy P et al. Improved mortality and rehabilitation of transplant candidates treated with a long-term implantable left ventricular assist system. Ann Surg 1995;222:327–36.
Frazier OH, Rose EA, Oz MC et al. Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation. J Thorac Cardiovasc Surg 2001;122:1186–95.
Griffith BP, Kormos RL, Borovetz HS et al. HeartMate II left ventricular assist system: from concept to first clinical use. Ann Thorac Surg 2001;71:Suppl:S116–20.
Haj-Yahia S, Birks EJ, Rogers P et al. Midterm experience with the Jarvik 2000 axial flow left ventricular assist device. J Thorac Cardiovasc Surg 2007;134:199–203.
Hetzer R, Jurmann MJ, Potapov EV et al. [Heart assist systems — current status.] Herz 2002;27:407–17.
Hetzer R, Weng Y, Potapov EV et al. First experiences with a novel magnetically suspended axial flow left ventricular assist device. Eur J Cardiothorac Surg 2004;25:964–70.
John R, Kamdar F, Liao K et al. Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy. Ann Thorac Surg 2008;86:1227–34.
Klotz S, Loeher A, Drees G et al. [Surgical therapy of end-stage heart failure. State of the art 2006.] Herz 2006;31:445–54.
Letsou GV, Shah N, Gregoric ID et al. Gastrointestinal bleeding from arteriovenous malformations in patients supported by the Jarvik 2000 axial-flow left ventricular assist device. J Heart Lung Transplant 2005;24:105–9.
Lietz K, Long JW, Kfoury AG et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation 2007;116:497–505.
Matthews JC, Koelling TM, Pagani FD et al. The right ventricular failure risk score, a pre-operative tool for assessing the risk of right ventricular failure in left ventricular assist device candidates. J Am Coll Cardiol 2008;51:2163–72.
McCarthy PM, Portner PM, Tobler HG et al. Clinical experience with the Novacor ventricular assist system. Bridge to transplantation and the transition to permanent application. J Thorac Cardiovasc Surg 1991;102:578–86.
McCarthy PM, Smedira NO, Vargo RL et al. One hundred patients with the HeartMate left ventricular assist device: evolving concepts and technology. J Thorac Cardiovasc Surg 1998;115:904–12.
Meyer AL, Kuehn C, Weidemann J et al. Thrombus formation in a HeartMate II left ventricular assist device. J Thorac Cardiovasc Surg 2008;135:203–4.
Miller LW, Pagani FD, Russell SD et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med 2007;357:885–96.
Noon GP, Morley DL, Irwin S et al. Clinical experience with the MicroMed DeBakey ventricular assist device. Ann Thorac Surg 2001;71:Suppl:S133–8.
Pennington DG, Kanter KR, McBride LR et al. Seven years’ experience with the Pierce-Donachy ventricular assist device. J Thorac Cardiovasc Surg 1988;96:901–11.
Pennington DG, Reedy JE, Swartz MT et al. Univentricular versus biventricular assist device support. J Heart Lung Transplant 1991;10:258–63.
Poelzl G, Frick M, Antretter H et al. Interventional and medical treatment of acute heart failure due to inflammation: four cases. Herz 2006;31:761–6.
Poerner TC, Ferrari M, Brehm BR et al. [Invasive therapeutic strategies in acute heart failure complicating coronary artery disease: effectiveness and boundaries.] Herz 2006;31:780–6.
Radovancevic B, Vrtovec B, de Kort E et al. End-organ function in patients on long-term circulatory support with continuous-or pulsatile-flow assist devices. J Heart Lung Transplant 2007;26:815–8.
Rose EA, Gelijns AC, Moskowitz AJ et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001;345:1435–43.
Sandner SE, Zimpfer D, Zrunek P et al. Renal function after implantation of continuous versus pulsatile flow left ventricular assist devices. J Heart Lung Transplant 2008;27:469–73.
Tuzun E, Roberts K, Cohn WE et al. In vivo evaluation of the HeartWare centrifugal ventricular assist device. Tex Heart Inst J 2007;34:406–11.
Wieselthaler GM, Riedl M, Schima H et al. Endocrine function is not impaired in patients with a continuous MicroMed-DeBakey axial flow pump. J Thorac Cardiovasc Surg 2007;133:2–6.
Zimpfer D, Wieselthaler G, Czerny M et al. Neurocognitive function in patients with ventricular assist devices: a comparison of pulsatile and continuous blood flow devices. ASAIO J 2006;52:24–7.
Author information
Authors and Affiliations
Corresponding author
Additional information
Erratum zu: HERZ 2008;33:556–60 DOI 10.1007/s00059-008-3179-0 Published online: 10 January 2008
Den Autoren sind unglücklicherweise auf Seite 559, linke Spalte, 2. Abschnitt, zwei Fehler unterlaufen. Sie möchten folgende Korrekturen anbringen (Änderungen in Fettschrift):
Demgegenüber wird im 2008 erschienenen deutschen Kommentar zu den o.g. Richtlinien keine prinzipielle Überlegenheit von Clopidogrel gegenüber ASS gesehen. Es wird eine Doppeltherapie (ASS plus Clopidogrel) nach Stentimplantation bei Vorhofflimmerpatienten mit einem CHADS2 -Score ≤ 1 empfohlen, und zwar für folgende Zeiträume: nach BMS für 4 Wochen, nach DES („drug- eluting stent“) für 6–12 Monate, nach Stenttherapie im Rahmen eines akuten Koronarsyndroms für 9 Monate [1]. Nach Stentimplantation sollte bei Vorhofflimmerpatienten mit einem CHADS2 -Score ≥ 2 für die o.g. Zeiträume entweder eine Kombinationstherapie (Vitamin-K-Antagonist plus ASS oder Vitamin-K-Antagonist plus Clopidogrel) oder eine Tripeltherapie (Vitamin-KAntagonist plus ASS plus Clopidogrel) durchgeführt werden [1]. Erfolgt eine Tripeltherapie, so empfehlen die aktuellen PCI-Richtlinien von 2007 aufgrund des erhöhten Blutungsrisikos einen Vitamin-K-Antagonisten mit Ziel-INR von 2,0–2,5 plus niedrigdosiertes ASS (75–81 mg/Tag) plus Clopidogrel 75 mg/Tag [9].
Rights and permissions
About this article
Cite this article
Antz, M., Hullmann, B., Neufert, C. et al. Antikoagulation bei Vorhofflimmern – Update. Herz 34, 140 (2009). https://doi.org/10.1007/s00059-009-3225-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00059-009-3225-6